KENALOG-10 (triamcinolone acetonide) by Bristol Myers Squibb is corticosteroid hormone receptor agonists [moa]. First approved in 1960.
Drug data last refreshed 18h ago · AI intelligence enriched Yesterday
KENALOG-10 is a corticosteroid injection containing triamcinolone acetonide that works as a hormone receptor agonist to reduce inflammation and immune response. Approved in 1960, it is used for intra-articular, intralesional, and soft tissue injection in various inflammatory and allergic conditions. The drug addresses patients requiring localized corticosteroid therapy with rapid anti-inflammatory effects.
As a legacy corticosteroid approaching loss of exclusivity with modest Part D spending and 290 claims annually, the brand team is likely focused on defensive positioning and cost management rather than aggressive growth initiatives.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Worked on KENALOG-10 at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on KENALOG-10 offers limited career growth opportunity given the LOE-approaching lifecycle, zero linked job postings, and modest commercial activity. This role suits professionals seeking stable, defensive portfolio management experience or those interested in generic transition strategy and market access.